财中社1月24日电 康哲药业(00867)发布公告,宣布与湖南麦济生物技术股份有限公司签订了关于1类新药MG-K10人源化单抗注射液的合作协议。根据协议,康哲药业获得了MG-K10在中国大陆、香港、澳门、台湾及新加坡的共同开发权和独家商业化权利,合作期限为永久。MG-K10是一种创新的长效抗IL-4Rα人源化单抗,主要用于治疗包括特应性皮炎、哮喘等多种2型炎症性疾病。MG-K10目前已进入中国的...
Source Link财中社1月24日电 康哲药业(00867)发布公告,宣布与湖南麦济生物技术股份有限公司签订了关于1类新药MG-K10人源化单抗注射液的合作协议。根据协议,康哲药业获得了MG-K10在中国大陆、香港、澳门、台湾及新加坡的共同开发权和独家商业化权利,合作期限为永久。MG-K10是一种创新的长效抗IL-4Rα人源化单抗,主要用于治疗包括特应性皮炎、哮喘等多种2型炎症性疾病。MG-K10目前已进入中国的...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.